#United States #Menlo Park #GLP-1 #Phenomix #MyPhenome

Phenomix Sciences Expands Evidence for MyPhenome™ Test

Phenomix Sciences, a leading biotechnology company specializing in precision obesity medicine, reported significant findings from their research at Obesity Week 2025. Their innovative MyPhenome™ test has demonstrated promising results in predicting patient responses to GLP-1 drugs, such as semaglutide, effectively identifying candidates across various demographics including post-bariatric surgery patients and ethnically diverse groups.

Two pivotal studies highlighted during the event confirmed the test's robust ability to forecast individual outcomes from GLP-1 therapies. One study specifically focused on post-bariatric surgery patients, revealing that those characterized by the ‘Hungry Gut’ phenotype experienced an average weight loss of 10% over six months, nearly twice the weight loss observed in those without this genetic marker.

Furthermore, the second study analyzed the efficacy of the MyPhenome test among a diverse cohort, including patients of African American, Asian, and other ethnicities. Results indicated that ‘Hungry Gut’ positive individuals lost approximately 9.6% of their total body weight within a year, significantly outperforming their ‘Hungry Gut’ negative counterparts who averaged only 4.4%.

Dr. Andres Acosta, co-founder of Phenomix Sciences and lead researcher at Mayo Clinic, commented on the findings, stating, "These results reiterate the MyPhenome test’s ability to accurately predict responses to semaglutide. This advancement marks a significant leap forward in precision obesity medicine, allowing us to anticipate treatment outcomes before initiating a plan."

A third extensive study, encompassing 88,200 patients, explored the MyPhenome test’s potential as a screening tool. The research underscored how individuals with higher Genetic Risk Scores (GRS) faced more considerable risks of developing conditions such as obesity and type 2 diabetes. Notably, it found that 46% of those with elevated GRS were classified as obese, compared to 31% among lower scores, indicating a pressing need for early intervention strategies.

Mark Bagnall, CEO of Phenomix Sciences, remarked on the significance of the data: "This comprehensive analysis supports our clinical findings by showcasing biological variability in obesity. Consequentially, the MyPhenome test not only enhances diagnostic capabilities but also paves the way for identifying novel therapeutic targets through artificial intelligence-based models. As we continue to investigate, we envision how this could revolutionize early intervention and preventive care methods."

The MyPhenome test itself is a non-invasive cheek swab, facilitating healthcare professionals in developing tailored treatment strategies that include dietary recommendations and potential pharmaceutical interventions. Currently, it is being utilized in nearly 400 healthcare clinics across the United States.

In closing, Phenomix Sciences emphasizes their commitment to transforming obesity management through individualized precision medicine, identifying not just how patients respond to treatments but also assisting pharmaceutical partners to refine their clinical trials and enhance the development of targeted therapies. This endeavor aligns with their partnership with the American Medical Association's innovation arm, Health2047, to escalate healthcare innovations that are crucial for improving outcomes in obesity care.

For more details about Phenomix Sciences and the encouraging research outcomes, visit their website at phenomixsciences.com.